ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory
Arrangements of Certain Officers.
On January 5, 2017, the Compensation Committee of the Board of
Directors of Adamis Pharmaceuticals Corporation (the Company)
approved the Companys 2017 Bonus Plan (the Plan) and approved the
corporate performance goals for 2017 under the Plan. The Plan is
substantially similar to the 2016 Bonus Plan approved last year
with respect to the 2016 year. The terms of the Plan generally
establish for each level of Company employee, including the
Companys executive officers but excluding the Companys field
sales employees, a target cash bonus amount, expressed as a
percentage of base salary. Bonus payments will be based on an
evaluation by the Compensation Committee of the Companys
achievement of corporate performance goals and, where applicable,
individual performance goals or other goals applicable to an
individual, for the relevant year. The corporate performance
goals for 2017 include the achievement of performance targets and
business goals tied to the Companys financial results, capital
raising and strategic activities, clinical development and
regulatory filings and approvals, clinical trials and product
development activities.
The foregoing description is a summary only, is not necessarily
complete, and is qualified by the full text of the underlying
plan, which is filed as an exhibit to this Current Report on Form
8-K.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits.
| 10.1 | Adamis Pharmaceuticals Corporation 2017 Bonus Plan* | |
| * Represents a compensatory plan of arrangement. |
About ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP)
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M). The Company’s product portfolio includes specialty pharmaceutical products, such as Epinephrine pre-filled syringe (PFS), APC-5000 dry powder inhaler (DPI), APC-1000 and APC-2000, and biotechnology products, such as TeloB-VAX (vaccine), APC-100, APC-200 and APC-300. The Company’s lead product candidate, the Epinephrine Injection USP 1:1000 0.3 milligram Pre-filled Single Dose Syringe, or the Epinephrine PFS, is a pre-filled syringe designed to deliver a premeasured 0.3 milligrams dose of epinephrine for the treatment of anaphylaxis. The Company also has licensed vaccine technology called somatic transgene immunization (STI) technology. ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) Recent Trading Information
ADAMIS PHARMACEUTICALS CORPORATION (NASDAQ:ADMP) closed its last trading session 00.00 at 3.45 with 402,001 shares trading hands.
